{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:35:48Z","timestamp":1792794948794,"version":"4.5.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","funder":[{"name":"Grant-in-Aid for Japan Research Foundation for Clinical Pharmacology","id":[{"id":"https:\/\/ror.org\/01t7fx814","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP22gk0110037 and JP23gn0110037"],"award-info":[{"award-number":["JP22gk0110037 and JP23gn0110037"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Valganciclovir (VGCV) is administered at a dose of 16 mg\/kg 2 times daily for 6 months to treat symptomatic congenital cytomegalovirus (CMV) infections. During the treatment period, approximately 20% of the patients developed grade 3 or higher neutropenia. Currently, information on the pharmacokinetics and pharmacodynamics of ganciclovir, an active metabolite of VGCV, in infants is limited. In the current study, the relationship between ganciclovir concentration and neutropenia was investigated, and a population pharmacokinetic (PPK) model of ganciclovir in infants with symptomatic congenital CMV infection was developed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Japanese infants who were prescribed oral VGCV for symptomatic congenital CMV infections between July 2017 and January 2021 were included. The relationship between the observed trough ganciclovir concentrations and neutrophil counts was examined. PPK analysis was performed to evaluate the covariates affecting the pharmacokinetics of ganciclovir.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Twenty-seven ganciclovir serum samples from 8 patients were analyzed. A moderate negative correlation was observed between the observed trough ganciclovir concentration and neutrophil count. PPK model analysis showed that postmenstrual age (PMA) affected the total body clearance of ganciclovir after correcting for the empirical allometric scaling of body weight. Based on PMA and body weight, a nomogram to achieve the target area under the concentration\u2013time curve from 0 to 24 hours of 40\u201360 mcg\u00b7h\u00b7mL\n                      <jats:sup>\u22121<\/jats:sup>\n                      of ganciclovir was calculated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The relationship between neutrophil count and ganciclovir trough concentration in infants was clarified. The PPK model showed that the dose of VGCV should be reduced in patients with a low PMA to achieve target exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001257","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T22:00:44Z","timestamp":1725487244000},"page":"393-399","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetic and Pharmacodynamic Assessment of Valganciclovir in Infants With Congenital Cytomegalovirus Infection"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7982-7881","authenticated-orcid":false,"given":"Kotaro","family":"Itohara","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Kobe University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kobe University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Fujinaka","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kobe University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kobe University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kobe University Hospital;"},{"name":"Department of Pharmaceutical Technology, Kobe Pharmaceutical University; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Kitahiro","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kobe University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Omura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kobe University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumichi","family":"Fujioka","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Graduate School of Medicine, Kobe University, Kobe, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuko","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kobe University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"R1-20250509","doi-asserted-by":"crossref","first-page":"105083","DOI":"10.1016\/j.antiviral.2021.105083","article-title":"Clinical outcome and the role of antivirals in congenital cytomegalovirus infection","volume":"191","author":"Ross","year":"2021","journal-title":"Antivir Res."},{"key":"R2-20250509","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa1404599","article-title":"Valganciclovir for symptomatic congenital cytomegalovirus disease","volume":"372","author":"Kimberlin","year":"2015","journal-title":"N Engl J Med."},{"key":"R3-20250509","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jiac.2020.08.019","article-title":"Efficacy, safety, and pharmacokinetics of oral valganciclovir in patients with congenital cytomegalovirus infection","volume":"27","author":"Suganuma","year":"2021","journal-title":"J Infect Chemother."},{"key":"R4-20250509","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.3390\/jcm11133582","article-title":"Oral valganciclovir therapy in infants aged \u22642 months with congenital cytomegalovirus disease: a multicenter, single-arm, open-label clinical trial in Japan","volume":"11","author":"Morioka","year":"2022","journal-title":"J Clin Med."},{"key":"R5-20250509","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003495-200161080-00016","article-title":"Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients","volume":"61","author":"McGavin","year":"2001","journal-title":"Drugs."},{"key":"R6-20250509","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","article-title":"Simplified calculation of body-surface area","volume":"317","author":"Mosteller","year":"1987","journal-title":"N Engl J Med."},{"key":"R7-20250509","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1600-6143.2008.02528.x","article-title":"Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients","volume":"9","author":"Vaudry","year":"2009","journal-title":"Am J Transpl."},{"key":"R8-20250509","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1097\/INF.0000000000001317","article-title":"Pharmacokinetics and safety of valganciclovir in pediatric heart transplant recipients 4 months of age and younger","volume":"35","author":"Bradley","year":"2016","journal-title":"Pediatr Infect Dis J."},{"key":"R9-20250509","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0022-3476(84)80479-5","article-title":"A simple estimate of glomerular filtration rate in full-term infants during the first year of life","volume":"104","author":"Schwartz","year":"1984","journal-title":"J Pediatr."},{"key":"R10-20250509","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0022-3476(85)80697-1","article-title":"A simple estimate of glomerular filtration rate in adolescent boys","volume":"106","author":"Schwartz","year":"1985","journal-title":"J Pediatr."},{"key":"R11-20250509","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0022-3476(86)80245-1","article-title":"A simple estimate of glomerular filtration rate in low birth weight infants during the first year of life: noninvasive assessment of body composition and growth","volume":"109","author":"Brion","year":"1986","journal-title":"J Pediatr."},{"key":"R12-20250509","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/psp4.12363","article-title":"Pediatric dosing of ganciclovir and valganciclovir: how model-based simulations can prevent underexposure and potential treatment failure","volume":"8","author":"Jorga","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"R13-20250509","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1086\/528376","article-title":"Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease","volume":"197","author":"Kimberlin","year":"2008","journal-title":"J Infect Dis."},{"key":"R14-20250509","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jiac.2024.03.006","article-title":"Assessment of patients' characteristics associated with the efficacy and safety of oral valganciclovir treatment for infants with symptomatic congenital cytomegalovirus disease","volume":"30","author":"Kakei","year":"2024","journal-title":"J Infect Chemother."},{"key":"R15-20250509","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/jps.23574","article-title":"A pharmacokinetic standard for babies and adults","volume":"102","author":"Holford","year":"2013","journal-title":"J Pharm Sci."},{"key":"R16-20250509","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.clpt.6100150","article-title":"Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation","volume":"81","author":"Acosta","year":"2007","journal-title":"Clin Pharmacol Ther."},{"key":"R18-20250509","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1447-0756.2001.tb01252.x","article-title":"Sonographic determination of fetal size from 20 weeks of gestation onward correlates with birth weight","volume":"27","author":"Yoshida","year":"2001","journal-title":"J Obstet Gynaecol Res."},{"key":"R20-20250509","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1542\/peds.2004-1915","article-title":"Age terminology during the perinatal period","volume":"114","author":"Engle","year":"2004","journal-title":"Pediatrics."},{"key":"R21-20250509","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02254-20","article-title":"Population pharmacokinetics of intravenous ganciclovir and oral valganciclovir in a pediatric population to optimize dosing regimens","volume":"65","author":"Nguyen","year":"2021","journal-title":"Antimicrob Agents Chemother."},{"key":"R22-20250509","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/cpt.449","article-title":"Bottom-up meets top-down: complementary physiologically based pharmacokinetic and population pharmacokinetic modeling for regulatory approval of a dosing algorithm of valganciclovir in very young children","volume":"100","author":"Jorga","year":"2016","journal-title":"Clin Pharmacol Ther."},{"key":"R23-20250509","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/00003088-200948050-00004","article-title":"Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients","volume":"48","author":"Zhao","year":"2009","journal-title":"Clin Pharmacokinet."},{"key":"R24-20250509","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/bcp.12343","article-title":"Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients","volume":"78","author":"Vezina","year":"2014","journal-title":"Br J Clin Pharmacol."},{"key":"R25-20250509","doi-asserted-by":"crossref","first-page":"e01192","DOI":"10.1128\/AAC.01192-19","article-title":"Population pharmacokinetics of ganciclovir after valganciclovir in renal transplant children","volume":"63","author":"Facchin","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"R26-20250509","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1111\/bcp.14719","article-title":"Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients","volume":"87","author":"Franck","year":"2021","journal-title":"Br J Clin Pharmacol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001257","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T08:00:25Z","timestamp":1746777625000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001257","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"assertion":[{"value":"2024-04-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}